BRPI0621081A2

BRPI0621081A2 - método de modulação de uma ou mais citocinas imuno-reguladoras, uso de um ou mais derivados de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos, método de inibição de uma resposta inflamatória e/ou de estimulação de uma resposta anti-inflamatória, método de tratamento e/ou de profilaxia de distúbios imunológicos, distúrbios inflamatórios e/ou distúrbios proliferativos celulares, agente imuno-modulador, agente anti-inflamatório ou agente anti-cáncer e um ou mais derivado de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos

método de modulação de uma ou mais citocinas imuno-reguladoras, uso de um ou mais derivados de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos, método de inibição de uma resposta inflamatória e/ou de estimulação de uma resposta anti-inflamatória, método de tratamento e/ou de profilaxia de distúbios imunológicos, distúrbios inflamatórios e/ou distúrbios proliferativos celulares, agente imuno-modulador, agente anti-inflamatório ou agente anti-cáncer e um ou mais derivado de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos Download PDF

Info

Publication number: BRPI0621081A2
Authority: BR; Brazil
Prior art keywords: chroman; phosphate; hydroxy; phosphate derivatives; cytokine
Prior art date: 2005-12-23

Application number

BRPI0621081-3A

Other languages

English (en)

Portuguese (pt)

Inventor

Esdra Ogru

Original Assignee

Vital Health Sciences Pty Ltd

Priority date

2005-12-23

Filing date

2006-12-22

Publication date

2011-11-29

2005-12-23 Priority claimed from AU2005907306A external-priority patent/AU2005907306A0/en

2006-12-22 Application filed by Vital Health Sciences Pty Ltd filed Critical Vital Health Sciences Pty Ltd

2011-11-29 Publication of BRPI0621081A2 publication Critical patent/BRPI0621081A2/pt

Links

108090000695 Cytokines Proteins 0.000 title claims description 139
102000004127 Cytokines Human genes 0.000 title claims description 138
238000011282 treatment Methods 0.000 title claims description 51
238000000034 method Methods 0.000 title claims description 49
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 44
230000004957 immunoregulator effect Effects 0.000 title claims description 20
208000027866 inflammatory disease Diseases 0.000 title claims description 19
208000026278 immune system disease Diseases 0.000 title claims description 18
230000028709 inflammatory response Effects 0.000 title claims description 16
230000002062 proliferating effect Effects 0.000 title claims description 14
238000011321 prophylaxis Methods 0.000 title claims description 14
239000002246 antineoplastic agent Substances 0.000 title claims description 9
230000002401 inhibitory effect Effects 0.000 title claims description 9
230000031990 negative regulation of inflammatory response Effects 0.000 title claims description 9
230000004936 stimulating effect Effects 0.000 title claims description 9
239000002260 anti-inflammatory agent Substances 0.000 title claims description 8
229940121363 anti-inflammatory agent Drugs 0.000 title claims description 7
239000003795 chemical substances by application Substances 0.000 title description 9
125000002887 hydroxy group Chemical group [H]O* 0.000 title description 4
125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 title description 3
230000002519 immonomodulatory effect Effects 0.000 title 1
239000000203 mixture Substances 0.000 claims description 101
-1 gamma tocopherol phosphate derivatives Chemical class 0.000 claims description 86
210000004027 cell Anatomy 0.000 claims description 61
150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 39
208000035475 disorder Diseases 0.000 claims description 33
230000000770 proinflammatory effect Effects 0.000 claims description 27
108090000623 proteins and genes Proteins 0.000 claims description 21
JUIUXBHZFNHITF-IEOSBIPESA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate Chemical class OP(=O)(O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C JUIUXBHZFNHITF-IEOSBIPESA-N 0.000 claims description 19
235000018102 proteins Nutrition 0.000 claims description 19
102000004169 proteins and genes Human genes 0.000 claims description 19
102000004889 Interleukin-6 Human genes 0.000 claims description 17
108090001005 Interleukin-6 Proteins 0.000 claims description 17
230000003110 anti-inflammatory effect Effects 0.000 claims description 17
102000004890 Interleukin-8 Human genes 0.000 claims description 14
108090001007 Interleukin-8 Proteins 0.000 claims description 14
VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims description 12
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 11
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 11
150000001413 amino acids Chemical class 0.000 claims description 10
239000008139 complexing agent Substances 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 7
239000002955 immunomodulating agent Substances 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
239000004475 Arginine Substances 0.000 claims description 5
102000003814 Interleukin-10 Human genes 0.000 claims description 5
108090000174 Interleukin-10 Proteins 0.000 claims description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
239000004472 Lysine Substances 0.000 claims description 5
206010054094 Tumour necrosis Diseases 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 5
150000001412 amines Chemical class 0.000 claims description 5
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
239000003102 growth factor Substances 0.000 claims description 5
239000000275 Adrenocorticotropic Hormone Substances 0.000 claims description 4
108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 4
102400000739 Corticotropin Human genes 0.000 claims description 4
101800000414 Corticotropin Proteins 0.000 claims description 4
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
108010051696 Growth Hormone Proteins 0.000 claims description 4
102000014150 Interferons Human genes 0.000 claims description 4
108010050904 Interferons Proteins 0.000 claims description 4
102000003982 Parathyroid hormone Human genes 0.000 claims description 4
108090000445 Parathyroid hormone Proteins 0.000 claims description 4
102100038803 Somatotropin Human genes 0.000 claims description 4
229960000258 corticotropin Drugs 0.000 claims description 4
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 4
230000012010 growth Effects 0.000 claims description 4
239000000122 growth hormone Substances 0.000 claims description 4
239000000199 parathyroid hormone Substances 0.000 claims description 4
229960001319 parathyroid hormone Drugs 0.000 claims description 4
239000011731 tocotrienol Substances 0.000 claims description 4
229930003802 tocotrienol Natural products 0.000 claims description 4
235000019148 tocotrienols Nutrition 0.000 claims description 4
230000000699 topical effect Effects 0.000 claims description 4
239000002076 α-tocopherol Substances 0.000 claims description 4
235000004835 α-tocopherol Nutrition 0.000 claims description 4
102000004877 Insulin Human genes 0.000 claims description 3
108090001061 Insulin Proteins 0.000 claims description 3
102000003816 Interleukin-13 Human genes 0.000 claims description 3
108090000176 Interleukin-13 Proteins 0.000 claims description 3
102000003810 Interleukin-18 Human genes 0.000 claims description 3
108090000171 Interleukin-18 Proteins 0.000 claims description 3
102000004388 Interleukin-4 Human genes 0.000 claims description 3
108090000978 Interleukin-4 Proteins 0.000 claims description 3
229940088597 hormone Drugs 0.000 claims description 3
239000005556 hormone Substances 0.000 claims description 3
229940125396 insulin Drugs 0.000 claims description 3
229940076144 interleukin-10 Drugs 0.000 claims description 3
229940028885 interleukin-4 Drugs 0.000 claims description 3
229940096397 interleukin-8 Drugs 0.000 claims description 3
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 3
125000004355 nitrogen functional group Chemical group 0.000 claims description 3
229910052700 potassium Inorganic materials 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
XYYUAOIALFMRGY-UHFFFAOYSA-N 3-[2-carboxyethyl(dodecyl)amino]propanoic acid Chemical compound CCCCCCCCCCCCN(CCC(O)=O)CCC(O)=O XYYUAOIALFMRGY-UHFFFAOYSA-N 0.000 claims description 2
102000055006 Calcitonin Human genes 0.000 claims description 2
108060001064 Calcitonin Proteins 0.000 claims description 2
102400000321 Glucagon Human genes 0.000 claims description 2
108060003199 Glucagon Proteins 0.000 claims description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
102000006992 Interferon-alpha Human genes 0.000 claims description 2
108010047761 Interferon-alpha Proteins 0.000 claims description 2
102000003996 Interferon-beta Human genes 0.000 claims description 2
108090000467 Interferon-beta Proteins 0.000 claims description 2
102000008070 Interferon-gamma Human genes 0.000 claims description 2
108010074328 Interferon-gamma Proteins 0.000 claims description 2
108010057464 Prolactin Proteins 0.000 claims description 2
239000002280 amphoteric surfactant Substances 0.000 claims description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
229960004015 calcitonin Drugs 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
239000003093 cationic surfactant Substances 0.000 claims description 2
238000006243 chemical reaction Methods 0.000 claims description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
229960004666 glucagon Drugs 0.000 claims description 2
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
229940100601 interleukin-6 Drugs 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
229940097325 prolactin Drugs 0.000 claims description 2
WGVKWNUPNGFDFJ-DQCZWYHMSA-N beta-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 claims 2
GZIFEOYASATJEH-VHFRWLAGSA-N delta-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 claims 2
210000003714 granulocyte Anatomy 0.000 claims 2
230000001131 transforming effect Effects 0.000 claims 2
GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 claims 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
102100024819 Prolactin Human genes 0.000 claims 1
102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 claims 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims 1
235000010389 delta-tocopherol Nutrition 0.000 claims 1
235000010382 gamma-tocopherol Nutrition 0.000 claims 1
150000004712 monophosphates Chemical class 0.000 claims 1
239000011590 β-tocopherol Substances 0.000 claims 1
235000007680 β-tocopherol Nutrition 0.000 claims 1
239000002478 γ-tocopherol Substances 0.000 claims 1
239000002446 δ-tocopherol Substances 0.000 claims 1
230000000694 effects Effects 0.000 description 51
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 42
206010028980 Neoplasm Diseases 0.000 description 27
238000009472 formulation Methods 0.000 description 27
239000000243 solution Substances 0.000 description 25
210000001616 monocyte Anatomy 0.000 description 24
235000012000 cholesterol Nutrition 0.000 description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
239000003981 vehicle Substances 0.000 description 19
241000283973 Oryctolagus cuniculus Species 0.000 description 17
230000004054 inflammatory process Effects 0.000 description 17
239000000725 suspension Substances 0.000 description 17
206010061218 Inflammation Diseases 0.000 description 16
241001465754 Metazoa Species 0.000 description 16
UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 14
230000002757 inflammatory effect Effects 0.000 description 14
239000000843 powder Substances 0.000 description 14
108010074051 C-Reactive Protein Proteins 0.000 description 13
102100032752 C-reactive protein Human genes 0.000 description 13
241000699670 Mus sp. Species 0.000 description 13
230000014509 gene expression Effects 0.000 description 13
210000000987 immune system Anatomy 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
208000023275 Autoimmune disease Diseases 0.000 description 12
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
150000001875 compounds Chemical class 0.000 description 12
230000004044 response Effects 0.000 description 12
201000011510 cancer Diseases 0.000 description 11
230000000260 hypercholesteremic effect Effects 0.000 description 11
101150041619 ATP25 gene Proteins 0.000 description 10
206010039491 Sarcoma Diseases 0.000 description 10
201000010099 disease Diseases 0.000 description 10
210000003491 skin Anatomy 0.000 description 10
102000019034 Chemokines Human genes 0.000 description 9
108010012236 Chemokines Proteins 0.000 description 9
206010025323 Lymphomas Diseases 0.000 description 9
208000009956 adenocarcinoma Diseases 0.000 description 9
230000006870 function Effects 0.000 description 9
238000013270 controlled release Methods 0.000 description 8
235000005911 diet Nutrition 0.000 description 8
230000037213 diet Effects 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
201000009030 Carcinoma Diseases 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000003755 preservative agent Substances 0.000 description 7
230000009696 proliferative response Effects 0.000 description 7
230000009885 systemic effect Effects 0.000 description 7
102000049320 CD36 Human genes 0.000 description 6
108010045374 CD36 Antigens Proteins 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 6
230000009471 action Effects 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
235000014113 dietary fatty acids Nutrition 0.000 description 6
239000000194 fatty acid Substances 0.000 description 6
229930195729 fatty acid Natural products 0.000 description 6
239000000499 gel Substances 0.000 description 6
230000028993 immune response Effects 0.000 description 6
210000000265 leukocyte Anatomy 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
229920000168 Microcrystalline cellulose Polymers 0.000 description 5
229910019142 PO4 Inorganic materials 0.000 description 5
102000003923 Protein Kinase C Human genes 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000006052 T cell proliferation Effects 0.000 description 5
238000000576 coating method Methods 0.000 description 5
230000007423 decrease Effects 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
239000000463 material Substances 0.000 description 5
239000008108 microcrystalline cellulose Substances 0.000 description 5
229940016286 microcrystalline cellulose Drugs 0.000 description 5
235000019813 microcrystalline cellulose Nutrition 0.000 description 5
235000021317 phosphate Nutrition 0.000 description 5
125000001095 phosphatidyl group Chemical group 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
206010041823 squamous cell carcinoma Diseases 0.000 description 5
239000003826 tablet Substances 0.000 description 5
101001127485 Arabidopsis thaliana Probable peroxidase 26 Proteins 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
206010024612 Lipoma Diseases 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 4
230000001594 aberrant effect Effects 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
235000010443 alginic acid Nutrition 0.000 description 4
229920000615 alginic acid Polymers 0.000 description 4
229960000686 benzalkonium chloride Drugs 0.000 description 4
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000001768 carboxy methyl cellulose Substances 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
239000006071 cream Substances 0.000 description 4
206010052015 cytokine release syndrome Diseases 0.000 description 4
230000006378 damage Effects 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
230000003511 endothelial effect Effects 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
229940014259 gelatin Drugs 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
239000008187 granular material Substances 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
MPNNOLHYOHFJKL-UHFFFAOYSA-N peroxyphosphoric acid Chemical class OOP(O)(O)=O MPNNOLHYOHFJKL-UHFFFAOYSA-N 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
210000002345 respiratory system Anatomy 0.000 description 4
230000035939 shock Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000007921 spray Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
239000000375 suspending agent Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical class OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 3
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
108010062271 Acute-Phase Proteins Proteins 0.000 description 3
102000011767 Acute-Phase Proteins Human genes 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
208000011231 Crohn disease Diseases 0.000 description 3
206010050685 Cytokine storm Diseases 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
201000008808 Fibrosarcoma Diseases 0.000 description 3
208000009329 Graft vs Host Disease Diseases 0.000 description 3
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
206010043276 Teratoma Diseases 0.000 description 3
206010052779 Transplant rejections Diseases 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
102100040247 Tumor necrosis factor Human genes 0.000 description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
229940087168 alpha tocopherol Drugs 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
230000037396 body weight Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000006172 buffering agent Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
201000001981 dermatomyositis Diseases 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
206010016629 fibroma Diseases 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
208000024908 graft versus host disease Diseases 0.000 description 3
201000011066 hemangioma Diseases 0.000 description 3
239000003906 humectant Substances 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
239000007943 implant Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
210000004969 inflammatory cell Anatomy 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000015788 innate immune response Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000002502 liposome Substances 0.000 description 3
206010025135 lupus erythematosus Diseases 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
239000004005 microsphere Substances 0.000 description 3
201000006417 multiple sclerosis Diseases 0.000 description 3
210000000653 nervous system Anatomy 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000006072 paste Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
229920001592 potato starch Polymers 0.000 description 3
238000011533 pre-incubation Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
229960000984 tocofersolan Drugs 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
206010001233 Adenoma benign Diseases 0.000 description 2
201000003076 Angiosarcoma Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000002927 Hamartoma Diseases 0.000 description 2
208000001258 Hemangiosarcoma Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
208000018142 Leiomyosarcoma Diseases 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
201000009906 Meningitis Diseases 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
208000037581 Persistent Infection Diseases 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
241000288906 Primates Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
208000008383 Wilms tumor Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000002730 additional effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
210000004100 adrenal gland Anatomy 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
208000003455 anaphylaxis Diseases 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
239000000090 biomarker Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
230000005907 cancer growth Effects 0.000 description 2
208000035269 cancer or benign tumor Diseases 0.000 description 2
208000002458 carcinoid tumor Diseases 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
230000020411 cell activation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
208000019065 cervical carcinoma Diseases 0.000 description 2
230000008859 change Effects 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
239000007859 condensation product Substances 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
235000020940 control diet Nutrition 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
102000003675 cytokine receptors Human genes 0.000 description 2
108010057085 cytokine receptors Proteins 0.000 description 2
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000036737 immune function Effects 0.000 description 2
239000003022 immunostimulating agent Substances 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
201000010260 leiomyoma Diseases 0.000 description 2
231100000636 lethal dose Toxicity 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
206010027191 meningioma Diseases 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
238000013508 migration Methods 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
239000002105 nanoparticle Substances 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
230000008481 normal tissue growth Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
201000009410 rhabdomyosarcoma Diseases 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
230000003381 solubilizing effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
231100001274 therapeutic index Toxicity 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229930003799 tocopherol Natural products 0.000 description 2
239000011732 tocopherol Substances 0.000 description 2
229940068778 tocotrienols Drugs 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical class FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
VCAMXEBNASZVEZ-UHFFFAOYSA-N 2,2-dimethyltetradecane Chemical compound CCCCCCCCCCCCC(C)(C)C VCAMXEBNASZVEZ-UHFFFAOYSA-N 0.000 description 1
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
KGALVPYTKQIBAA-UHFFFAOYSA-N 2-methyl-3,4-dihydro-2h-chromene Chemical class C1=CC=C2OC(C)CCC2=C1 KGALVPYTKQIBAA-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010048998 Acute phase reaction Diseases 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
235000002198 Annona diversifolia Nutrition 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000023514 Barrett esophagus Diseases 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000019838 Blood disease Diseases 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000009458 Carcinoma in Situ Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102000011632 Caseins Human genes 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
206010008263 Cervical dysplasia Diseases 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
201000009047 Chordoma Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
206010048832 Colon adenoma Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
208000007033 Dysgerminoma Diseases 0.000 description 1
206010014612 Encephalitis viral Diseases 0.000 description 1
208000010334 End Stage Liver Disease Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
241001331845 Equus asinus x caballus Species 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
208000005917 Exostoses Diseases 0.000 description 1
206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
208000007659 Fibroadenoma Diseases 0.000 description 1
102100037362 Fibronectin Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
206010053717 Fibrous histiocytoma Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
208000000527 Germinoma Diseases 0.000 description 1
208000007569 Giant Cell Tumors Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
201000005409 Gliomatosis cerebri Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
206010018404 Glucagonoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
102000014702 Haptoglobin Human genes 0.000 description 1
108050005077 Haptoglobin Proteins 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
102000013271 Hemopexin Human genes 0.000 description 1
108010026027 Hemopexin Proteins 0.000 description 1
208000032456 Hemorrhagic Shock Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019629 Hepatic adenoma Diseases 0.000 description 1
208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
206010023330 Keloid scar Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
241000282838 Lama Species 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
208000002404 Liver Cell Adenoma Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
201000003791 MALT lymphoma Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
206010027145 Melanocytic naevus Diseases 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
208000014767 Myeloproliferative disease Diseases 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
PHSRRHGYXQCRPU-AWEZNQCLSA-N N-(3-oxododecanoyl)-L-homoserine lactone Chemical compound CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O PHSRRHGYXQCRPU-AWEZNQCLSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
201000004404 Neurofibroma Diseases 0.000 description 1
208000007256 Nevus Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
208000031662 Noncommunicable disease Diseases 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
241000243985 Onchocerca volvulus Species 0.000 description 1
206010031149 Osteitis Diseases 0.000 description 1
208000000035 Osteochondroma Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010058674 Pelvic Infection Diseases 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
102100038124 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
206010037596 Pyelonephritis Diseases 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
208000005678 Rhabdomyoma Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000282887 Suidae Species 0.000 description 1
206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
206010045168 Tumour embolism Diseases 0.000 description 1
208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
208000009311 VIPoma Diseases 0.000 description 1
206010047112 Vasculitides Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
241001416177 Vicugna pacos Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
206010048214 Xanthoma Diseases 0.000 description 1
206010048215 Xanthomatosis Diseases 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
229940048053 acrylate Drugs 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
210000005006 adaptive immune system Anatomy 0.000 description 1
208000002718 adenomatoid tumor Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229940009868 aluminum magnesium silicate Drugs 0.000 description 1
WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
210000002403 aortic endothelial cell Anatomy 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
208000035362 autoimmune disorder of the nervous system Diseases 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
201000004339 autoimmune neuropathy Diseases 0.000 description 1
208000006424 autoimmune oophoritis Diseases 0.000 description 1
201000004982 autoimmune uveitis Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
208000018339 bone inflammation disease Diseases 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000003149 breast fibroadenoma Diseases 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
201000002143 bronchus adenoma Diseases 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
239000000828 canola oil Substances 0.000 description 1
235000019519 canola oil Nutrition 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
235000005487 catechin Nutrition 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940074979 cetyl palmitate Drugs 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
229960003260 chlorhexidine Drugs 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
201000005217 chondroblastoma Diseases 0.000 description 1
230000008711 chromosomal rearrangement Effects 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
208000011444 chronic liver failure Diseases 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
229950001002 cianidanol Drugs 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
206010011005 corneal dystrophy Diseases 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
229960002887 deanol Drugs 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012972 dimethylethanolamine Substances 0.000 description 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000003372 endocrine gland Anatomy 0.000 description 1
239000003532 endogenous pyrogen Substances 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
206010014801 endophthalmitis Diseases 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960004667 ethyl cellulose Drugs 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
201000010934 exostosis Diseases 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
201000000052 gastrinoma Diseases 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
201000003115 germ cell cancer Diseases 0.000 description 1
208000024693 gingival disease Diseases 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
208000006359 hepatoblastoma Diseases 0.000 description 1
201000002735 hepatocellular adenoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
229960003943 hypromellose Drugs 0.000 description 1
208000009326 ileitis Diseases 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
201000004933 in situ carcinoma Diseases 0.000 description 1
208000033065 inborn errors of immunity Diseases 0.000 description 1
201000001371 inclusion conjunctivitis Diseases 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000013256 infectious meningitis Diseases 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
210000005007 innate immune system Anatomy 0.000 description 1
206010022498 insulinoma Diseases 0.000 description 1
210000002570 interstitial cell Anatomy 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
208000022013 kidney Wilms tumor Diseases 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
239000008141 laxative Substances 0.000 description 1
238000010150 least significant difference test Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000865 liniment Substances 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000007885 magnetic separation Methods 0.000 description 1
238000002826 magnetic-activated cell sorting Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
201000004593 malignant giant cell tumor Diseases 0.000 description 1
201000000289 malignant teratoma Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
230000000897 modulatory effect Effects 0.000 description 1
210000002864 mononuclear phagocyte Anatomy 0.000 description 1
208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000002346 musculoskeletal system Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000009091 myxoma Diseases 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
208000009928 nephrosis Diseases 0.000 description 1
231100001027 nephrosis Toxicity 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
201000004662 neurofibroma of spinal cord Diseases 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
208000002042 onchocerciasis Diseases 0.000 description 1
201000005737 orchitis Diseases 0.000 description 1
230000008520 organization Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
208000003388 osteoid osteoma Diseases 0.000 description 1
208000008798 osteoma Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
238000007427 paired t-test Methods 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000021255 pancreatic insulinoma Diseases 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000002304 perfume Substances 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229940049953 phenylacetate Drugs 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
208000024724 pineal body neoplasm Diseases 0.000 description 1
201000004123 pineal gland cancer Diseases 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
230000036178 pleiotropy Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
208000028529 primary immunodeficiency disease Diseases 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229940127293 prostanoid Drugs 0.000 description 1
150000003814 prostanoids Chemical class 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
239000011814 protection agent Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
230000001543 purgative effect Effects 0.000 description 1
238000010926 purge Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
208000029922 reticulum cell sarcoma Diseases 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000001593 sorbitan monooleate Chemical class 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000002381 testicular Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229940042585 tocopherol acetate Drugs 0.000 description 1
150000003611 tocopherol derivatives Chemical class 0.000 description 1
125000002640 tocopherol group Chemical class 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
206010044325 trachoma Diseases 0.000 description 1
238000013271 transdermal drug delivery Methods 0.000 description 1
206010044412 transitional cell carcinoma Diseases 0.000 description 1
230000014616 translation Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000005671 trienes Chemical class 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
208000022271 tubular adenoma Diseases 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
201000002498 viral encephalitis Diseases 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1